Faze Three Limited (NSE:FAZE3Q)
India · Delayed Price · Currency is INR 538.60
-13.60 (-2.46%)
Aug 7, 2025, 11:30 AM IST
Sage Therapeutics Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 6,899 | 5,645 | 5,582 | 5,045 | 3,244 | Upgrade |
Other Revenue | - | - | - | - | 0.4 | Upgrade |
| 6,899 | 5,645 | 5,582 | 5,045 | 3,244 | Upgrade | |
Revenue Growth (YoY) | 22.22% | 1.14% | 10.65% | 55.50% | 7.26% | Upgrade |
Cost of Revenue | 3,424 | 2,621 | 2,465 | 2,311 | 1,587 | Upgrade |
Gross Profit | 3,475 | 3,025 | 3,117 | 2,733 | 1,657 | Upgrade |
Selling, General & Admin | 1,037 | 820.6 | 692.3 | 651.9 | 516.2 | Upgrade |
Other Operating Expenses | 1,634 | 1,302 | 1,454 | 1,257 | 666.9 | Upgrade |
Operating Expenses | 2,921 | 2,326 | 2,291 | 2,011 | 1,272 | Upgrade |
Operating Income | 554 | 698.4 | 826.1 | 722.5 | 385.8 | Upgrade |
Interest Expense | -145.5 | -112.5 | -78.4 | -49.9 | -37.7 | Upgrade |
Interest & Investment Income | - | 50.9 | 35.5 | 23.1 | 15.7 | Upgrade |
Currency Exchange Gain (Loss) | - | -27.3 | -19.6 | 32.7 | -13.9 | Upgrade |
Other Non Operating Income (Expenses) | 118 | 9.8 | 0.1 | 3.6 | 2.2 | Upgrade |
EBT Excluding Unusual Items | 526.5 | 619.3 | 763.7 | 732 | 352.1 | Upgrade |
Gain (Loss) on Sale of Investments | - | 10.2 | 14.4 | 2.1 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | -4 | -0.7 | - | 1.2 | Upgrade |
Asset Writedown | - | -1 | -1.2 | -20.1 | - | Upgrade |
Pretax Income | 526.5 | 624.5 | 776.2 | 714 | 353.3 | Upgrade |
Income Tax Expense | 119.9 | 158.6 | 193.2 | 203.2 | 104 | Upgrade |
Net Income | 406.6 | 465.9 | 583 | 510.8 | 249.3 | Upgrade |
Net Income to Common | 406.6 | 465.9 | 583 | 510.8 | 249.3 | Upgrade |
Net Income Growth | -12.73% | -20.09% | 14.13% | 104.89% | 37.43% | Upgrade |
Shares Outstanding (Basic) | 24 | 24 | 24 | 24 | 24 | Upgrade |
Shares Outstanding (Diluted) | 24 | 24 | 24 | 24 | 24 | Upgrade |
Shares Change (YoY) | -0.00% | - | - | - | - | Upgrade |
EPS (Basic) | 16.72 | 19.16 | 23.97 | 21.00 | 10.25 | Upgrade |
EPS (Diluted) | 16.72 | 19.16 | 23.97 | 21.00 | 10.25 | Upgrade |
EPS Growth | -12.72% | -20.08% | 14.14% | 104.88% | 37.41% | Upgrade |
Free Cash Flow | -803.5 | -232.3 | 553.2 | -391.7 | -52.4 | Upgrade |
Free Cash Flow Per Share | -33.04 | -9.55 | 22.75 | -16.11 | -2.15 | Upgrade |
Dividend Per Share | - | - | 0.500 | - | - | Upgrade |
Gross Margin | 50.37% | 53.58% | 55.84% | 54.19% | 51.09% | Upgrade |
Operating Margin | 8.03% | 12.37% | 14.80% | 14.32% | 11.89% | Upgrade |
Profit Margin | 5.89% | 8.25% | 10.45% | 10.13% | 7.69% | Upgrade |
Free Cash Flow Margin | -11.65% | -4.12% | 9.91% | -7.76% | -1.62% | Upgrade |
EBITDA | 804.3 | 869.9 | 942 | 803.2 | 452 | Upgrade |
EBITDA Margin | 11.66% | 15.41% | 16.88% | 15.92% | 13.93% | Upgrade |
D&A For EBITDA | 250.3 | 171.5 | 115.9 | 80.7 | 66.2 | Upgrade |
EBIT | 554 | 698.4 | 826.1 | 722.5 | 385.8 | Upgrade |
EBIT Margin | 8.03% | 12.37% | 14.80% | 14.32% | 11.89% | Upgrade |
Effective Tax Rate | 22.77% | 25.40% | 24.89% | 28.46% | 29.44% | Upgrade |
Revenue as Reported | 7,017 | 5,723 | 5,638 | 5,114 | 3,267 | Upgrade |
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.